Joo MD - Design Therapeutics CEO Pres
| DSGN Stock | USD 5.53 0.05 0.91% |
Insider
Joo MD is CEO Pres of Design Therapeutics
| Age | 61 |
| Address | 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011 |
| Phone | 858 293 4900 |
| Web | https://www.designtx.com |
Design Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1354) % which means that it has lost $0.1354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1778) %, meaning that it created substantial loss on money invested by shareholders. Design Therapeutics' management efficiency ratios could be used to measure how well Design Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to grow to -0.27. At this time, Design Therapeutics' Other Current Assets are very stable compared to the past year. As of the 21st of November 2024, Asset Turnover is likely to grow to 0.000007, while Total Assets are likely to drop about 232.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| James Foster | Virax Biolabs Group | 39 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.14 |
Design Therapeutics Leadership Team
Elected by the shareholders, the Design Therapeutics' board of directors comprises two types of representatives: Design Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Design. The board's role is to monitor Design Therapeutics' management team and ensure that shareholders' interests are well served. Design Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Design Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aseem Ansari, CoFounder Advisor | ||
| Sean Jeffries, Chief Officer | ||
| Elizabeth Gordon, Senior Affairs | ||
| Pratik Shah, President CoFounder | ||
| Mustapha Parekh, General Counsel | ||
| Joo MD, CEO Pres | ||
| MD FACC, Consulting Officer | ||
| Dawn Giangiulio, Controller | ||
| Julie CPA, Chief Officer |
Design Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Design Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 58.73 M | ||||
| Shares Outstanding | 56.62 M | ||||
| Shares Owned By Insiders | 36.45 % | ||||
| Shares Owned By Institutions | 56.84 % | ||||
| Number Of Shares Shorted | 2.59 M | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (48.61 M) |
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Design Stock
| 0.52 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.5 | KALV | Kalvista Pharmaceuticals | PairCorr |
| 0.49 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.49 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.47 | INZY | Inozyme Pharma | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.